Exploratory biomarker analysis for progression during adaptive androgen deprivation therapy for metastatic castration sensitive prostate cancer.
Sign Up to like & getrecommendations! Published in 2025 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2025.43.16_suppl.e17095
Abstract: e17095 Background: When cure is not feasible, adaptive therapy can provide better control of metastatic cancer by delaying the evolution of treatment resistance. For patients with metastatic castrate sensitive prostate cancer (mCSPC), we previously reported… read more here.
Keywords: psa progression; progression; psa testosterone; therapy ... See more keywords